TickerTalks
Browse all tickers →
TickerTalks›$MTD
MTMTD

Mettler-Toledo International Inc.

$MTD·$29B·Medical - Diagnostics & Research·Healthcare
$1405.14+0.5%YTD-1.3%1Y+10.1%
Mentions · last 7 days
2026-08-22: 1 posts2026-08-23: 0 posts40%
Price updated 8h ago·X counts updated 8d ago
MTMTD
$MTDMettler-Toledo International Inc.
$1,405.14+0.47%4 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $MTD, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-29

The move is getting stronger, with heavier trading behind it.

Precision-instruments compounder with 36% ROIC + steady beat cadence; Vadala $2.67M option exercise is the insider signal.

Mettler-Toledo International is a $28.89B global precision instruments + services provider (laboratory + industrial + food retail) at $1398.58 — -1.3% YTD, +9% t12m, sitting at 75% of its 52w range and near-flat vs 200d.

  • Q2 EPS $11.46 vs $10.85 (+5.6% beat), Q1 $8.91 vs $8.71 (+2.3%), Q4 2025 $13.36 vs $12.80 (+4.4%) — narrow consistent beats.
  • Q1 revenue $947M (+7.2% YoY), Q4 2025 $1.13B (+8.1%) — solid mid-single-digit growth.
  • Cash economics: PE 26.8, PS 5.70, ROIC 36% (exceptional), ROE -6.1% (data artifact — negative equity from buybacks), gross margin 58%, op-margin 28%, D/E -53.2 (repurchase-driven negative equity), EV/EBITDA 20.6, FCF yield 3.4%.
  • Analyst path FY26 EPS $46.67 → FY27 $51.12 (+9.5% growth) — steady compounding.
  • Insider signal: 8 events — Salice $332K + $601K, Vadala $2.67M M-Exempt (large option-exercise), Keller S-Sale $343K — meaningful distributional cluster into steady operations.
  • New director Natalia Shuman appointed (Aug 3), expanding board from 9 to 10 members.
  • Zacks Upgraded to Buy rating.
  • Sentiment feed is empty.

Read as a quality-of-earnings precision-instruments compounder with 36% ROIC + moat-quality economics + steady beat-and-raise cadence; the debated question is whether Q3 confirms the mid-single-digit growth pace or whether recent insider distribution flags concentration risk we haven't seen yet.

What to watch: Q3 organic revenue growth, additional Vadala/Salice insider transactions, and Zacks Buy conversion on the Nov 5 print.

On the calendar: 2026-11-05 Q3 earnings

Read the AI verdict + X sentiment for $MTD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes precision laboratory balances, analytical instruments, and process weighing systems for pharma and food industries.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $MTD.

Medical - Diagnostics & Research · Healthcare

Diagnostic testing volumes are normalizing post-COVID elevated baseline; liquid biopsy and genomic sequencing are the structural growth areas. Reimbursement rate changes (CMS updates) are the primary margin risk for established lab businesses.

What this means for $MTD

Partial — upstream oil & gas exposure ties to commodity price cycle; Mettler-Toledo International Inc.

Industry benchmark

21-name peer basket
+37.3%YTD
+76.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
26.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
36.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
28.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-6.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
57.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-53.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$11.46$10.85+5.6%
Q1 2026May 7, 2026$8.91$8.71+2.3%
Q4 2025Feb 5, 2026$13.36$12.80+4.4%
Q3 2025Nov 6, 2025$11.15$10.66+4.6%
Next earningsThu, Nov 5·consensus EPS $12.11

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$947.1M+7.2%58.7%26.0%$8.35$122.4M
Q4 FY25$1.1B+8.1%58.0%30.4%$14.02$184.1M
Q3 FY25$1.0B+7.9%57.2%28.2%$10.60$274.9M
Q2 FY25$983.2M+3.9%57.2%27.0%$9.77$212.5M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$4.2B$4.2B – $4.3B$46.67$46.45 – $46.818
FY27$4.4B$4.4B – $4.4B$51.12$50.45 – $51.798
FY28$4.7B$4.6B – $4.7B$56.87$56.82 – $56.936
FY29$4.9B$4.9B – $4.9B$63.20$62.77 – $63.765
FY30$5.2B$5.1B – $5.2B$70.51$70.04 – $71.133

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.76%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+4.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+6.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 20.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.225-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 5Thomas P SaliceDirector417 sh$601KSellAug 3Thomas P SaliceDirector415 sh$600KSellAug 3Gerry KellerHead of Process Analytics240 sh$343KSellAug 3Shawn VadalaCFO2.2K sh$3.2M
+ 10 other (6 awards · 4 exempts) in window

See when $MTD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 53
AI summary

Natalia Shuman-Fabbri filed an initial Form 3 on August 5, 2026, reporting her appointment as a Director of Mettler-Toledo International Inc. (MTD) as of August 3, 2026. She beneficially owns no Mettler-Toledo securities at the time of filing. This is a routine Section 16 administrative filing confirming the addition of a new board member to the Swiss-headquartered precision instruments and laboratory equipment company; it carries no financial or strategic implications.

8-KOfficer or director changeAug 38-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Mettler-Toledo International Inc. appointed Natalia Shuman as an independent director effective August 3, 2026, expanding the board from nine to ten members; committee assignments have not yet been determined. Ms. Shuman's compensation will be consistent with other independent directors as described in the March 2026 proxy. Routine administrative board expansion, with no financial impact.

8-KOfficer or director changeMay 138-K — Item 5.02: Officer or director change
AI summary

MTD disclosed a personnel change (8-K Item 5.02, dated 2026-05-13). A new executive or director appointment is reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KShareholder voteMay 118-K — Item 5.07: Shareholder vote
AI summary

MTD held its annual meeting of stockholders around 2026-05-11 (8-K Item 5.07). The meeting was adjourned, likely due to insufficient quorum. Routine governance event — monitor for unusually high withhold votes as an activist signal.

+ 13 other (4 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Bank of Nova Scotia Takes $4.22 Million Position in Mettler-Toledo International, Inc. $MTDdefenseworld.net·6d agoMettler-Toledo (MTD) Upgraded to Buy: Here's Whyzacks.com·11d agoWhat Investors Should Know About a Mettler-Toledo Director's Two Transactions This Past Weekfool.com·21d agoWhat Investors Should Know as Mettler-Toledo Insiders Sell Shares After a Strong Quarterfool.com·21d agoA Mettler-Toledo Director Sold $600,000 in Stock. Here's What Investors Should Knowfool.com·21d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$TWST$PSNL$A$ILMN$NTRA$GH$TMO
Voices on X · last 7 days

No standout posts about $MTD on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport